Journal
ENDOCRINE
Volume 52, Issue 3, Pages 414-426Publisher
SPRINGER
DOI: 10.1007/s12020-016-0888-7
Keywords
Osteoporosis; Sclerostin; Cathepsin K; Pycnodystostosis; Van Buchem disease; Sclerosteosis
Categories
Funding
- Amgen
- Axsome
- Merck Co
- Novartis
- UCB
Ask authors/readers for more resources
During the past 15 years there has been an expansion of our knowledge of the cellular and molecular mechanisms regulating bone remodeling that identified new signaling pathways fundamental for bone renewal as well as previously unknown interactions between bone cells. Central for these developments have been studies of rare bone disorders. These findings, in turn, have led to new treatment paradigms for osteoporosis some of which are at late stages of clinical development. In this article, we review three rare skeletal disorders with case descriptions, pycnodysostosis and the craniotubular hyperostoses sclerosteosis and van Buchem disease that led to the development of cathepsin K and sclerostin inhibitors, respectively, for the treatment of osteoporosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available